Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... FRANCISCO , July 30, 2015 ... market is expected to reach USD 23.01 million ... View Research, Inc. Growing base of geriatric population, increasing ... infections, and rising level of awareness among target customer ... rendering drivers over the forecast period. According to estimates ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
... Cloud-based Veeva CRM Now Deployed in Over 20 European ... Customer Summit kicking off this morning in Philadelphia, Veeva Systems ... Since Veeva,s official expansion into Europe in April 2010, the ... than 35 life sciences companies across 20+ different European markets. ...
... AB (OMX: MVIR), a research-based specialty pharmaceutical company focused ... Henric Juserius to be the new head of the ... for Medivir,s pharmaceutical marketing and sales, will join the ... the management team. Henric Juserius has a ...
Cached Medicine Technology:Veeva Systems Announces Dramatic Growth in Europe 2Veeva Systems Announces Dramatic Growth in Europe 3Veeva Systems Announces Dramatic Growth in Europe 4New Executive Vice President Commercial Appointed 2
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to ... Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based call ... display logic shows the script components to the agent only when wanted, and allows ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... to release a newly redesigned website at Healthpointe.net. The new website will feature ... , The redesign serves to provide smoother interactions between patients and the ...
(Date:7/31/2015)... ... ... According to WFLA on July 16th, Sarasota has seen at ... Thricefold deaths have held steady over the last “couple of months” according to WFLA. ... was spurred by the crackdown of prescription painkillers. Many users who were addicted to ...
(Date:7/31/2015)... Michigan (PRWEB) , ... July 31, 2015 , ... ... baby at Beaumont Hospital's Karmanos Center for Natural Birth . The ... looking for a safe natural childbirth experience. With nurses and caregivers that are ...
(Date:7/31/2015)... ... 2015 , ... EB Medicine, leading publisher of clinical journals, ... to announce that it has partnered with AgileMD to release Pediatric Emergency ... Android smartphones and tablets. , “The April 2015 launch of our flagship ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Healthpointe Announces Newly Redesigned Website 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3
... taking antioxidants during pregnancy may prevent birth defects in ... mice // were exposed to ethanol and also given ... malformations in the offspring. Ethanol is the intoxicating agent ... alcoholics isn’t the best, people who are alcoholic by ...
... disease may be able to stop or even slightly ... a surgical procedure to implant // embryonic cells into ... dopamine, a neurochemical that helps control movement. People with ... movement problems common in people with the condition. ...
... HAART, the cytomegalovirus was a major problem for AIDS ... and led to faster progression of the disease and ... status in about 375 people infected with HIV using ... years, noting new cases of CMV disease, development of ...
... million men in the United States suffer from erectile ... for men. With exercise and weight loss // , ... improve their sexual function say researchers. ,Researchers, conducted ... losing weight and an increase in physical activity, would ...
... than 40,000 new cases of head and neck cancer are ... annually.// Researchers say there are about 500,000 new cases worldwide ... in a new study say they are disabled by their ... were observed , of the 348 patients, 52 percent were ...
... new study shows dogs may be able to anticipate ... from the dogs in this study was // ... activity, whimpering, and “protective" behavior without aggression. In previous ... abort or even prevent their seizures. Some breeds ...
Cached Medicine News:
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il...
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 3.5V halogen source....
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 2.5V halogen source....
All metal construction with fiber optic illumination. Large diameter viewing port, insufflation port, and swivelling airtight window....
Medicine Products: